Candida species uncommonly cause vertebral osteomyelitis. We present a case of lumbar vertebral osteomyelitis caused by Candida albicans and review 59 cases of candidal vertebral osteomyelitis reported in the literature. The mean age was 50 years, and the lower thoracic or lumbar spine was involved in 95% of patients. Eightythree percent of patients had back pain for 11 month, 32% presented with fever, and 19% had neurological deficits. The erythrocyte sedimentation rate was elevated in 87% of patients, and blood culture yielded Candida species for 51%. C. albicans was responsible for 62% of cases, Candida tropicalis for 19%, and Candida glabrata for 14%. Risk factors for candidal vertebral osteomyelitis were the presence of a central venous catheter, antibiotic use, immunosuppression, and injection drug use. Medical and surgical therapies were both used, and amphotericin B was the primary antifungal agent. Prognosis was good, with an overall clinical cure rate of 85%.
The widespread use of central venous catheters, broadspectrum antibiotics, and immunosuppressive medications has significantly changed the microbiological spectrum of diseases encountered by physicians. Organisms typically considered commensal or those associated with low virulence are becoming increasingly important pathogens. The ubiquitous yeast Candida is now the fourth leading cause of nosocomial bloodstream infections in the United States and can cause invasive disease in the setting of reduced immune system competence [1] . Unfortunately, effective antifungal agents are limited and frequently associated with significant toxicities [2] . We report a case of vertebral osteomyelitis caused by Candida albicans in an injection drug user and review the published literature on previously reported cases of this rare disease.
METHODS
We conducted a MEDLINE search of the English literature from 1966 through October 2000 and a bibliographic search of published articles to identify clearly documented cases of vertebral osteomyelitis caused by Candida species. To classify cases as definitive candidal vertebral osteomyelitis, we required radiographic, laboratory, or clinical evidence of osteomyelitis and a diagnosis of candidiasis based on the results of either culture or histologic examination of a biopsy specimen. In one case in the literature, the pathological diagnosis was made at autopsy. All other cases were diagnosed antemortem. We reviewed all available data, including clinical presentation, laboratory results, therapeutic interventions, and outcome.
CASE REPORT
A 25-year-old white woman with a 2-year history of injection drug use was admitted to the hospital for chronic and progressive lumbar back pain. She had used iv heroin and cocaine almost daily for 2 years and routinely used lemon juice to dissolve crack cocaine before injection. Her past medical history was unremarkable except for multiple episodes of cellulitis that required treatment with iv antibiotics. There was no history of endocarditis, and results of repeated HIV tests had been negative. Her back pain had been present for 9 months and was unrelated to any specific trauma. The pain radiated to her left hip and upper thigh but was not associated with any neurological deficits or other systemic symptoms except infrequent night sweats.
The patient was afebrile, and her physical examination was unremarkable except for diffuse lumbar midline and paraspinal muscle tenderness. Results of neurological examination were normal. Results of laboratory tests were as follows: WBC count, 4.4 cells/mm 3 , with a normal differential; erythrocyte sedimentation rate (ESR), 57 mm/h; C-reactive protein level, 2 mg/dL; and liver function tests, normal. Culture of blood samples yielded no pathogens and serological testing for HIV-1 and HIV-2 was negative. MRI of the lumbar spine showed L4-5 diskitis and osteomyelitis. Gram's staining of multiple CT-guided biopsy specimens from the L4-5 region showed no organisms and rare polymorphonuclear leukocytes. Culture of 2 separate spinal biopsy specimens yielded C. albicans within 48 h.
The patient began treatment with iv amphotericin B at a dosage of 0.5 mg/kg/day for 4 weeks (total dose, 850 mg) followed by treatment with oral fluconazole at a dosage of 400 mg/day. After the patient completed treatment with amphotericin B and 4 weeks of oral fluconazole, her back pain had improved, her ESR had decreased to 29 mm/h, and her Creactive protein level had normalized. Another 2 weeks of oral fluconazole was planned; however, the patient was lost to further follow-up, and therefore no further imaging studies or clinical evaluations were performed.
RESULTS
Clinical characteristics of the 59 patients identified in a literature review and the 1 case patient presented in this report are shown in tables 1 and 2. These patients include 13 from 4 from small published case series [5, 14, 24, 34] . The average age of patients was 50 years (range, !1-88 years). The majority of patients were 40-80 years old. However, for a group of patients aged 16-25 years, injection drug use was the primary risk factor for disseminated candidiasis. There was a slightly elevated ratio of males to females (1.4:1). All patients for whom clinical data were available presented with back pain, 32% of patients presented with fever, and 19% had neurological deficits at presentation. Symptoms were present in 83% of patients for 11 month before the diagnosis was made, and 29% had symptoms for 13 months. There was no significant difference in the duration of symptoms between patients who presented with neurological deficits ( months, ) and patients who 3.7 ‫ע‬ 2.4 n p 9 presented without neurological deficits ( months, 2.8 ‫ע‬ 2.3 ;
). The lower thoracic or lumbosacral spine was n p 38 P 1 .3 involved in 95% of patients, and disease was restricted to a narrow spinal column region in all but 2 patients.
The primary laboratory abnormality reported in patients with candidal vertebral osteomyelitis was an elevated ESR (87% of patients). Only 17% of patients had elevated WBC counts.
Other laboratory values were either normal or not reported. Culture results confirmed the diagnosis of candidiasis for 57 of 60 patients. Three patients had histological evidence of candidal vertebral osteomyelitis; C. albicans was cultured from a sample of intra-abdominal fluid from 1 of these 3. All other patients had Candida species isolated from a vertebral biopsy or autopsy specimen, and 51% of patients had concordant blood culture results. Six different Candida species were recovered. The predominant species was C. albicans, which was recovered from 62% of patients. There were also 11 cases of vertebral osteomyelitis due to Candida tropicalis (19%) and 8 cases due to Candida glabrata (14%). Both C. glabrata and C. tropicalis were isolated from the culture of a vertebral biopsy specimen from 1 patient, and the remainder of cases were monomicrobial.
Previous studies have identified several risk factors associated with fungemia and invasive candidiasis, including antibiotic use, placement of a central venous catheter, steroid use or other immunosuppression, surgery, and placement of a urinary catheter [49, 50] . We identified similar risk factors for patients with candidal vertebral osteomyelitis: 53% of patients had central venous catheters, 50% had been treated with antibiotics, and 37% were immunosuppressed. We also identified injection drug use as a risk factor for 22% of patients, a finding consistent with previous reports that invasive candidiasis is related to parenteral drug abuse [4, 7, 14, 24] . The remaining risk factors were a collection of clinical conditions, such as underlying malignancy, surgery, diabetes, and alcohol abuse, which theoretically predisposed the patients to develop invasive disease from normally low-virulence organisms.
The treatments for patients with candidal vertebral osteomyelitis were varied and consisted of both surgical and medical interventions. A total of 23 patients received a combined medical-surgical intervention, and 31 patients received only medical therapy. The primary surgical interventions were debridement, bone grafting, and vertebral fusion, although 5 patients also required prosthetic supports to be implanted. Systemic amphotericin B was the primary antifungal agent and was used to treat all but 1 patient infected with C. glabrata. The average duration of amphotericin B therapy for both medical and surgical patients was 6-7 weeks, with a total dose of 1-2 g. However, there was substantial variation in the duration of treatment, from 1 week to 4 months. Only 3 patients were treated with lipid formulations of amphotericin B, and 14 patients initially received amphotericin B followed by an azole. Eight patients, all of whom were infected with C. albicans, received no amphotericin B and were treated only with an azole. Azole therapy was more prolonged than amphotericin B therapy and generally lasted 5-6 months. However, similar to amphotericin B treatment, there was substantial variability in the duration of azole therapy; the shortest duration was 4 weeks and the longest was 1 year. The majority of patients with candidal vertebral osteomyelitis were cured, as judged by the results of follow-up clinical, radiographic, or laboratory evaluations. Only 2 patients underwent additional biopsies to demonstrate a microbiological cure. Unfortunately, follow-up was not reported for 4 cases, and 3 additional patients were lost to extended follow-up. All of the latter 3 patients had injection drug use as a risk factor, as for the patient described in this report. When only patients for whom follow-up was available were included, candidal vertebral osteomyelitis was cured in 45 (85%) of 53 patients. Overwhelming invasive candidiasis was the hypothesized primary cause of death for 2 patients; it was reported that 1 was infected with C. tropicalis and 1 with an unnamed species of Candida. An additional 6 patients died of causes unrelated to candidal vertebral osteomyelitis. Five were infected with C. albicans and 1 with C. tropicalis. When only patients for whom follow-up was available were included, the overall mortality associated with candidal vertebral osteomyelitis was 15%.
DISCUSSION
Vertebral bone infections caused by fungi are uncommon. A recent review of vertebral osteomyelitis caused by Aspergillus species describes only 41 cases in the published literature [51] . Cases of fungal vertebral osteomyelitis caused by the endemic fungi Coccidioides immitis and Blastomyces dermatitidis have also been described [52] [53] [54] [55] . We encountered a case of vertebral osteomyelitis caused by C. albicans and searched the medical literature for similar cases. Candida species are typically considered commensal organisms and either part of the normal human flora or associated with clinically benign infections, such as yeast vaginitis [56] . However, in the presence of impaired host immunity or repeated intravascular access, Candida species can become invasive pathogens. Our review of the published literature from 1966 through 2000 revealed only 59 previously reported cases of candidal vertebral osteomyelitis.
The increasing incidence of invasive candidiasis has led to the identification of patient characteristics associated with invasive disease from a typically low-virulence organism. Multivariate analyses have identified several risk factors for invasive candidiasis: receipt of antibiotics, presence of a central venous catheter, receipt of parenteral nutrition, hemodialysis, surgery, burns, neutropenia, and the isolation of Candida organisms from 12 body sites [49, 50] . These risk factors change the patients' natural flora, increase the risk for candidemia from an intravascular device, or produce some level of immunosuppression. The majority of patients with candidal vertebral osteomyelitis had had an indwelling central venous catheter, had received antibiotics, or were immunosuppressed. Therefore, certain previously identified risk factors for invasive candidiasis apply to candidal vertebral osteomyelitis as well.
We identified injection drug use as a significant risk factor for the development of candidal vertebral osteomyelitis. Parenteral drug use is a well-recognized risk factor for disseminated fungal disease. Leen and Breetle [57] estimate that ∼20% of hospital admissions of injection drug users are for fungal infections, hypothetically from drug paraphernalia contaminated with skin and oral flora. Candida endocarditis predominantly due to Candida parapsilosis has been closely linked with injection drug use [58] . However, the most interesting association of injection drug use and invasive candidiasis is a distinctive disseminated syndrome of cutaneous, ocular, and osteoarticular candidiasis seen in patients who use injection heroin [14, 59, 60] . This syndrome consists of an acute episode of fever and chills, followed several days later by the development of painful cutaneous nodules and several weeks later by chorioretinitis or anterior uveitis. The final stage of the syndrome is osteoarticular involvement, which occurs weeks to months after the initial symptoms and involves primarily costochondral regions, although the spine is also frequently involved [14, 60] . Epidemiological and laboratory studies traced the potential source of Candida contamination to lemon juice used to dissolve the injected heroin [61] [62] [63] [64] . Curiously, our patient used lemon juice to dissolve her crack cocaine before injection and even commented that the lemons frequently appeared moldy.
Vertebral osteomyelitis can occur either through direct extension of a contiguous infection or via hematogenous seeding from a distant focus of infection [65] . Hematogenous dissemination is thought to be the primary pathophysiological mechanism of vertebral osteomyelitis in adults [66] , in part because of the extensive vascular supply around the vertebrae and intervening disks [67] . Although only 51% of patients had blood culture results that were positive for Candida species, we suspect that the majority of cases of candidal vertebral osteomyelitis reported in the literature and reviewed in this report were hematogenous in origin. Only 4 patients had clearly described trauma or surgery at the infected vertebral level before developing osteomyelitis, and 1 of these also had an antecedent episode of candidemia. Therefore, a patient with subacute or chronic back pain and a history of candidemia, even when the episode of candidemia occurred months to years earlier [45] , should prompt an investigation for possible candidal vertebral osteomyelitis.
The clinical and laboratory characteristics of patients with candidal vertebral osteomyelitis were similar to those described for patients with bacterial [65] and Aspergillus [51] vertebral osteomyelitis. With the exception of patients who used injection drugs, the majority of patients with candidal vertebral osteomyelitis were 40-80 years old, and there was a slight predominance of male patients. The typical patient presented with back pain in the lower thoracic to lumbosacral spine, usually with at least 1 month of symptoms before diagnosis. Only one-third of patients had fever at presentation. About 20% of patients had neurological deficits, similar to the 17% reported for bacterial osteomyelitis [65] . Results of laboratory tests other than microbiological tests were nonspecific; they frequently consisted of an elevated ESR but a normal WBC count, which are results similar to those for patients with Aspergillus vertebral osteomyelitis [51] . Therefore, clinical and standard laboratory parameters are insufficient to definitively diagnose candidal vertebral osteomyelitis.
The diagnosis of candidal vertebral osteomyelitis begins with a high clinical index of suspicion, followed by appropriate radiographic studies and confirmation with microbiological tests. Plain radiographs frequently show erosive and destructive vertebral changes, but these may not be visible for weeks to months [68] . Although CT scanning can identify earlier bony changes and can also evaluate the presence of paravertebral or spinal canal extension [69] , candidal vertebral osteomyelitis has no characteristic CT findings [31] . In contrast, Williams et al. [29] reported several characteristic MRI findings in 3 cases of fungal vertebral osteomyelitis that distinguished those cases from bacterial vertebral osteomyelitis. Although further studies are needed to confirm these findings, MRI should be considered the imaging modality of choice for vertebral osteomyelitis [70] .
The definitive microbiological diagnosis of candidal vertebral osteomyelitis requires culture of a biopsy specimen. The differential diagnosis of back pain for which MRI reveals inflammatory changes is broad. It includes infections from bacteria, mycobacteria, fungi, and other unusual or fastidious organisms, and also malignancies such as multiple myeloma and metastatic disease. Therefore, every effort must be made to make a definitive diagnosis. Multiple needle biopsy specimens should be obtained of the vertebral bodies, intervening disks, and paravertebral soft tissues, if imaging studies show that they are involved. These biopsies should be performed with fluoroscopic or CT guidance, which in experienced hands has a negligible complication rate [71] . For all biopsy specimens, specific fungal and mycobacterial studies should be performed, in addition to routine stain, culture, and histological examination. If the results for initial needle biopsy specimens are negative, the procedure should be repeated. If a second set of needle biopsy specimens still yields negative results, then strong consideration should be given to performing an open biopsy, because empirical therapies for bacterial, mycobacterial, or fungal osteomyelitis are vastly different and associated with toxicities that require close monitoring.
The specific Candida species should also be definitively identified to guide therapy, because invasive candidiasis caused by species other than C. albicans is increasing in frequency [72] . Antifungal susceptibilities of Candida species are variable. For example, C. albicans is routinely susceptible to fluconazole, Candida krusei is routinely resistant, and C. glabrata can have a variable resistance pattern [72, 73] . We identified C. albicans as the predominant organism responsible for reported cases of candidal vertebral osteomyelitis. However, more than one-third of cases involved species other than C. albicans, including 8 cases due to C. glabrata, an organism that is frequently resistant to fluconazole [73] . The role of routine antifungal susceptibility testing is unclear; large clinical studies correlating in vitro susceptibilities with clinical responses have not been reported. However, reproducible methods have been developed for in vitro testing of Candida species for susceptibility to fluconazole and itraconazole [74] . We suggest azole antifungal susceptibility testing when species other than C. albicans and C. krusei are isolated or when C. albicans is isolated and the patient has previously received intensive treatment with an azole antifungal agent, because fluconazole-resistant C. albicans isolates have been recovered from HIV-infected patients after prolonged azole therapy [75] . The treatment of candidal vertebral osteomyelitis in the published literature was varied and involved both surgical and medical interventions. Surgical intervention was rarely the sole treatment and was generally used to make a definitive diagnosis when examination of biopsy specimens was not diagnostic, to decompress the spinal canal when radiographic or clinical features suggested spinal cord impingement, or to provide stability in the face of extensive disease or unstable anatomic location, such as cervical spine involvement. The primary medical regimen was administration of either amphotericin B alone for 1-2 months or amphotericin B followed by a prolonged course of an oral azole.
We contemplated using fluconazole therapy alone to treat our patient, because financial and psychosocial issues precluded home parenteral therapy with amphotericin B. We identified 7 cases of C. albicans vertebral osteomyelitis in the published literature that had been treated successfully with azole therapy alone [9, 14, 21, 23, 24] . Ketoconazole alone has been used successfully to treat patients who used injection drugs and who had the disseminated candidiasis syndrome [14, 60] , and candidal sternal osteomyelitis has been cured with fluconazole [36] . However, clinical failures with fluconazole therapy have been reported [76] . Because of the potential serious complications of inadequate treatment for vertebral osteomyelitis, we chose to use the best available parenteral antifungal agent initially, followed by a less toxic oral agent. On the basis of our review of the published data for cases of candidal vertebral osteomyelitis, we recommend 4-6 weeks of systemic amphotericin B therapy at a dosage of 0.5-1.0 mg/kg/day, followed by 2-6 months of treatment with an oral azole when susceptible organisms are isolated. The total length of therapy has to be determined empirically, but we recommend treatment until the ESR normalizes, symptoms resolve clinically, and imaging studies show resolution of inflammatory changes. These recommendations are consistent with recently published Infectious Diseases Society of America practice guidelines for the treatment of candidiasis [77] . With the advent of new and less toxic antifungal agents [78] , alternative regimens for candidal vertebral osteomyelitis may soon become available.
The prognosis for patients with candidal vertebral osteomyelitis is good. The majority of patients were clinically cured in the absence of significant comorbidities, an outcome profile similar to that for patients with bacterial vertebral osteomyelitis [65] . The 85% cure rate for reported cases of candidal vertebral osteomyelitis likely underestimates the actual achievable cure rate, because for most patients who were lost to follow-up or who died of unrelated causes, clinical improvement was noted initially. Similarly, the 15% mortality rate is likely an overestimation, because most of the patients who died had significant comorbidities, and only 2 patients died of presumed disseminated candidiasis.
Candidal vertebral osteomyelitis is a rare disease. A high clinical index of suspicion is required for patients presenting with subacute or chronic low back pain, even in the absence of fever, if the patients have risk factors for disseminated candidiasis, such as a history of central venous access, antibiotic use, immunosuppression, and/or injection drug use. Performance of MRI and biopsies with appropriate cultures is essential for accurate and definitive diagnosis. Prognosis is generally good with prolonged antifungal therapy, starting initially with parenteral amphotericin B followed by an extended course of an oral azole for susceptible Candida species.
